Key facts
- It has raised $16.3M; the latest was Accelerator/Incubator in Sep 2024.
- Notable investors include Verve Ventures, Boehringer Ingelheim Venture Fund, UV-Cap Private Equity, BonVenture, German Accelerator — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for glucura
- ·The full record, as it builds
Funding rounds
No funding rounds for glucura are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About glucura
Developer of commercialized digital therapeutics designed to offer personalized low-glycemic diets. The company has developed a proprietary dataset and patent-pending algorithms that are deployed across a pipeline of digital therapeutics and show drug-like effectiveness without unintended side effects and address the root causes of diseases, enabling individuals with personalized dietary adjustments delivered through fun and engaging digital experiences.
- Sector
- Healthcare
- HQ
- Lubeck, Germany
- Founded
- 2017
- Employees
- 32
- Website
- glucura.de/
- Ownership
- Privately Held (backing)
glucura doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in glucura shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on glucura in its N-PORT filings yet. We sweep new filings monthly.